Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 17/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595868 | 0.92 | CACNA1H (0.78) | CACNA1HMEN1ALDH1A1RECQLKMT2A | |
| SCHEMBL13595933 | 0.90 | CACNA1H (0.75) | CACNA1HALDH1A1 | |
| SCHEMBL13595939 | 0.89 | CACNA1H (0.74) | CACNA1HLMNAMEN1KMT2A | |
| SCHEMBL13595923 | 0.89 | CACNA1H (0.74) | CACNA1HLMNA | |
| SCHEMBL13595884 | 0.89 | CACNA1H (0.84) | CACNA1HALDH1A1 | |
| SCHEMBL13596382 | 0.89 | CACNA1H (0.76) | CACNA1H | |
| SCHEMBL13595926 | 0.87 | CACNA1H (0.71) | CACNA1HLMNAALDH1A1 | |
| SCHEMBL13595875 | 0.87 | CACNA1H (0.83) | CACNA1H | |
| SCHEMBL13595879 | 0.86 | CACNA1H (0.70) | CACNA1HALDH1A1 | |
| SCHEMBL13595909 | 0.86 | CACNA1H (0.73) | CACNA1HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | GPR119, PNLIP, CYP46A1 | CACNA1H 1192/4885LMNA 4180/4885MEN1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.